Acute myeloid leukemia (AML) is a heterogeneous hematopoietic neoplasm which results in
clonal proliferation of abnormally differentiated hematopoietic cells. In this review …

Simple Summary Bispecific T-cell engagers (BiTEs) and bispecific antibodies (BiAbs) have
emerged as novel therapeutic modalities in the treatment of advanced hematological …

Dual-specificity, tyrosine phosphorylation-regulated kinases (DYRKs) and cdc2-like kinases
(CLKs) play a large variety of cellular functions and are involved in several diseases …

Breast cancer, which is the most common malignant tumor among women worldwide and an
important cause of death in women. The existing prognostic model for patients with breast …

Acute myeloid leukemia (AML) is a heterogeneous malignancy affecting myeloid cells in the
bone marrow (BM) but can spread giving rise to impaired hematopoiesis. AML incidence …

Fms-like tyrosine kinase 3 (FLT3) has been validated as a therapeutic target for acute
myeloid leukemia (AML). While a number of FLT3 kinase inhibitors have been approved for …

FMS-like tyrosine kinase 3 (FLT3) is mutated in approximately 30% of acute myeloid
leukemia (AML) patients. The presence of FLT3-ITD (internal tandem duplication, 20–25%) …

Acute myeloid leukemia (AML) is a highly aggressive illness distinguished by the
accumulation of abnormal hematopoietic precursors in both the bone marrow and peripheral …

Purpose: Breast cancer is a highly heterogeneous malignancy, seriously threatening female
health worldwide and inducing higher mortalities. Few have the studies evaluated Fms-like …

Acute myeloid leukemia (AML) patients often experience poor therapeutic outcomes and
relapse after treatment with single-target drugs, representing the urgent need of new …